ScripThe NASDAQ Biotech Index is down by nearly 27% since the last peak, the IPO window is virtually shut, there is diminished appetite for secondary offerings, the situation has been made worse by the col
ScripWhile it is human nature to expect a CEO of a company that has been successful to go on to repeat their triumphs, success may be down to luck or turn out to be elusive in more challenging assignments.